BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. Jansen-Storbacka succeeds Rod Sears-Black, who retired earlier this year, with CEO Adriaan Moelker temporarily overseeing the role during the interim period. This leadership appointment represents a significant strategic move for the company as it seeks to enhance its position in the rapidly evolving biotechnology sector.
With over 20 years of experience in biotechnology, Jansen-Storbacka brings extensive expertise in enzyme applications across industrial processes, animal nutrition, and home care sectors. He holds both an M.Sc. in Engineering and Management and an MBA, providing him with the technical and business acumen required for this critical leadership position. His international experience and proven leadership skills position him as an ideal fit for leading the enzyme products business segment during a period of industry transformation.
In his new role, Jansen-Storbacka will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. The company operates multiple facilities globally, including production sites detailed at https://www.biocatalysts.com/. His appointment signals BRAIN Biotech's strategic commitment to strengthening its enzyme and fermentation business while ensuring closer integration of research and production activities across the organization.
Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable in serving diverse end markets. The company specializes in researching, developing, and producing specialty enzymes for the food and life sciences industries, while also developing microbial production strains and scalable bioprocesses for economic protein production. More information about the company's operations can be found at https://www.brain-biotech-group.com/.
The appointment comes as BRAIN Biotech continues to expand its global footprint and enhance its position in the biologization of industry. The company reported revenue of €54.6 million in the 2023/24 fiscal year and employs approximately 300 people worldwide. This leadership change represents a strategic move to drive growth and innovation, particularly in enzyme applications that support more sustainable products and efficient industrial processes across multiple sectors including food, life sciences, and industrial manufacturing.
